Miele, Luca
 Distribuzione geografica
Continente #
EU - Europa 10.052
AS - Asia 9.476
NA - Nord America 9.254
SA - Sud America 2.084
AF - Africa 246
OC - Oceania 34
Continente sconosciuto - Info sul continente non disponibili 26
Totale 31.172
Nazione #
US - Stati Uniti d'America 8.948
SG - Singapore 4.614
DE - Germania 2.838
CN - Cina 2.550
IT - Italia 2.053
BR - Brasile 1.745
SE - Svezia 1.626
IE - Irlanda 564
UA - Ucraina 518
FR - Francia 458
GB - Regno Unito 428
NL - Olanda 399
ID - Indonesia 388
VN - Vietnam 386
IN - India 321
FI - Finlandia 310
RU - Federazione Russa 248
TR - Turchia 196
HK - Hong Kong 166
KR - Corea 163
AR - Argentina 150
BD - Bangladesh 143
CA - Canada 135
PL - Polonia 134
IQ - Iraq 103
JP - Giappone 103
AT - Austria 92
BE - Belgio 87
MX - Messico 87
ZA - Sudafrica 60
CH - Svizzera 54
ES - Italia 54
IR - Iran 47
PK - Pakistan 44
EC - Ecuador 43
CZ - Repubblica Ceca 42
SA - Arabia Saudita 42
MA - Marocco 35
CO - Colombia 32
KE - Kenya 32
LT - Lituania 31
EG - Egitto 29
UZ - Uzbekistan 27
AU - Australia 26
CL - Cile 26
VE - Venezuela 26
CI - Costa d'Avorio 24
AE - Emirati Arabi Uniti 21
PY - Paraguay 20
EU - Europa 19
PT - Portogallo 19
AZ - Azerbaigian 18
RO - Romania 18
JO - Giordania 17
PA - Panama 15
JM - Giamaica 14
PH - Filippine 14
TN - Tunisia 14
DZ - Algeria 13
IL - Israele 13
PE - Perù 13
UY - Uruguay 13
CR - Costa Rica 12
HU - Ungheria 12
NP - Nepal 12
TT - Trinidad e Tobago 12
BO - Bolivia 11
LB - Libano 10
OM - Oman 10
AL - Albania 9
GR - Grecia 9
KZ - Kazakistan 8
NZ - Nuova Zelanda 8
GE - Georgia 7
KG - Kirghizistan 7
BG - Bulgaria 6
DK - Danimarca 6
DO - Repubblica Dominicana 6
ET - Etiopia 6
HN - Honduras 6
MD - Moldavia 6
MY - Malesia 6
BZ - Belize 5
EE - Estonia 5
GY - Guiana 5
LK - Sri Lanka 5
SY - Repubblica araba siriana 5
BH - Bahrain 4
HR - Croazia 4
NG - Nigeria 4
QA - Qatar 4
RE - Reunion 4
SV - El Salvador 4
AO - Angola 3
BY - Bielorussia 3
CY - Cipro 3
GT - Guatemala 3
IS - Islanda 3
KW - Kuwait 3
SC - Seychelles 3
Totale 31.107
Città #
Singapore 2.088
Chandler 1.092
Ashburn 1.036
Dublin 562
Hefei 483
Beijing 474
New York 409
Chicago 375
Jakarta 364
Rome 344
Los Angeles 302
Jacksonville 291
Milan 291
Dallas 264
Frankfurt am Main 252
San Mateo 251
Nanjing 205
Munich 186
Boston 161
Moscow 161
Hong Kong 157
Nürnberg 154
Ann Arbor 153
Wilmington 150
Houston 148
Seoul 146
São Paulo 145
Helsinki 137
Kent 135
Ho Chi Minh City 134
Izmir 124
Marseille 116
Princeton 113
Dearborn 107
The Dalles 105
Cattolica 104
Hanoi 93
Nuremberg 90
Seattle 87
Brussels 86
Tokyo 86
Woodbridge 86
Nanchang 77
Santa Clara 77
Boardman 76
Brooklyn 67
Rio de Janeiro 64
Buffalo 62
London 62
Hyderabad 57
Redmond 55
Warsaw 55
Atlanta 51
Kraków 50
Fairfield 49
Tianjin 48
Redwood City 47
Turku 47
Hebei 45
Shenyang 43
Poplar 42
Denver 41
Zurich 41
Baghdad 40
Guangzhou 40
Stockholm 40
Düsseldorf 39
Montreal 39
Amsterdam 38
Bremen 38
Lawrence 38
Dhaka 37
San Jose 37
Vienna 37
Zhengzhou 37
Phoenix 36
Toronto 35
Belo Horizonte 34
Brasília 34
Brno 34
Kunming 34
San Francisco 34
Johannesburg 31
Mountain View 30
North Bergen 30
Norwalk 30
Orem 30
Shanghai 30
Changsha 29
Pune 29
Chennai 28
Curitiba 28
Lappeenranta 28
Nairobi 27
Washington 27
Hangzhou 25
Lauterbourg 25
Mexico City 25
Palermo 25
Abidjan 24
Totale 14.605
Nome #
A multi-society Delphi consensus statement on new fatty liver disease nomenclature 1.216
Differentiating hepatocellular carcinoma from dysplastic nodules at gadobenate dimeglumine-enhanced hepatobiliary-phase magnetic resonance imaging 442
Asthma in patients admitted to emergency department for COVID-19: prevalence and risk of hospitalization 254
Ombitasvir, paritaprevir, and ritonavir, with or without dasabuvir, plus ribavirin for patients with hepatitis C virus genotype 1 or 4 infection with cirrhosis (ABACUS): a prospective observational study 251
13C-methionine breath tests for mitochondrial liver function assessment. 245
A phase II study of sunitinib in advanced hepatocellular carcinoma 244
gc) Increased intestinal permeability and tight junction alterations in nonalcoholic fatty liver disease. 228
Caucasian lean subjects with non-alcoholic fatty liver disease share long-term prognosis of non-lean: Time for reappraisal of BMI-driven approach? 228
13C-breath tests in the study of microsomal liver function 224
-Hepatic steatosis and vascular disease 214
Prevalence, characteristics and severity of non-alcoholic fatty liver disease in patients with chronic plaque psoriasis 213
Severe veno-occlusive disease after autologous peripheral blood stem cell transplantation for high-grade non-Hodgkin lymphoma: report of a successfully managed case and a literature review of veno-occlusive disease. 201
134C-breath tests in the study of mitochondrial liver function 200
A machine-learning parsimonious multivariable predictive model of mortality risk in patients with Covid-19 199
Role of diffusion-weighted imaging, apparent diffusion coefficient and correlation with hepatobiliary phase findings in the differentiation of hepatocellular carcinoma from dysplastic nodules in cirrhotic liver 196
Non-alcoholic fatty liver disease is associated with high prevalence of gastro-oesophageal reflux symptoms 189
Non Alcoholic Fatty Liver Disease is Associated with Increased GHBP and Reduced GH/IGF-I Levels 186
Non-alcoholic fatty liver disease is associated with high prevalence of gastro-oesophageal reflux symptoms 186
Ethanol injection is highly effective for hepatocellular carcinoma smaller than 2 cm 183
Effect of sildenafil on diabetic gastropathy. 178
13C-breath tests in the study of microsomial liver function 178
13C-methionine breath tests for mitochondrial liver function assessment 172
Assessment of neurological manifestations in hospitalized patients with COVID-19 172
The Effect of CYP, GST, and SULT Polymorphisms and Their Interaction with Smoking on the Risk of Hepatocellular Carcinoma 162
Hepatocellular carcinoma treated by conventional transarterial chemoembolization in field-practice: serum sodium predicts survival 158
[Oxidative stress in metabolic syndrome and nonalcoholic steatohepatitis. Is it possible a role for vitamins in clinical practice?] 156
Non Alcoholic Fatty Liver Disease is Associated with Increased GHBP and Reduced GH/IGF-I Levels 154
Liver transplantation in patients with alcoholic liver disease: A retrospective study 154
Nonalcoholic fatty liver disease (NAFLD) severity is associated to a nonhemostatic contribution and proinflammatory phenotype of platelets 154
Gemelli decision tree Algorithm to Predict the need for home monitoring or hospitalization of confirmed and unconfirmed COVID-19 patients (GAP-Covid19): preliminary results from a retrospective cohort study 153
Cryoglobulinemia: a true internistic disease? 153
Nonalcoholic fatty liver disease is associated with increased GHBP and reduced GH/IGF-I levels 153
gc) Celiac disease in the 21st century: issues of under- and over-diagnosis 153
Intestinal permeability after Mediterranean diet and low-fat diet in non-alcoholic fatty liver disease 153
13C-breath tests in the study of mitochondrial liver function 151
[Helicobacter pylori infection: from gastric to systemic disease] 151
A multi-society Delphi consensus statement on new fatty liver disease nomenclature 148
Noninvasive assessment of fibrosis in non-alcoholic fatty liver disease (NAFLD) and non-alcoholic steatohepatitis (NASH). 148
Potential use of liver function breath tests in the clinical practice. 147
Solving the mystery of HBV-related mixed cryoglobulinemia: potential biomarkers of disease progression 147
Long-term metformin treatment is able to reduce the prevalence of metabolic syndrome and its hepatic involvement in young hyperinsulinaemic overweight patients with polycystic ovarian syndrome 145
-Fatty liver and drugs 143
Prevalence, characteristics and severity of non-alcoholic fatty liver disease in patients with chronic plaque psoriasis 143
Therapeutic Approach to Post-Transplant Recurrence of Hepatocellular Carcinoma: Certainties and Open Issues 141
[The treatment of hepatocellular carcinoma: an update] 140
gastroesophageal reflux disease: facts and uncertaines 139
High Prevalence and Gender-Related Differences of Gastrointestinal Manifestations in a Cohort of DM1 Patients: A Perspective, Cross-Sectional Study 138
Intrafamilial transmission of hepatitis C virus in Italy: a systematic review 137
A case-control study on the effects of the apolipoprotein E genotypes in nonalcoholic fatty liver disease 134
Cystic lymphangioma of the mesentery and hyposplenism in celiac disease. 133
Genetic susceptibility of increased intestinal permeability is associated with progressive liver disease and diabetes in patients with non-alcoholic fatty liver disease 132
Tromboembolism and breast cancer: the hidden risk for patient and physician 131
Autoimmunity and lymphoproliferation markers in naïve HCV-RNA positive patients without clinical evidences of autoimmune/lymphoproliferative disorders 131
Clinical characteristics of metabolic associated fatty liver disease (MAFLD) in subjects with myotonic dystrophy type 1 (DM1) 131
Reverse time-dependent effect of alphafetoprotein and disease control on survival of patients with Barcelona Clinic Liver Cancer stage C hepatocellular carcinoma 129
A case-control study on the effect of metabolic gene polymorphisms, nutrition, and their interaction on the risk of non-alcoholic fatty liver disease 128
An Attempt of Specific Desensitizing Treatment with Gliadin in Coleliac Disease 127
Long-term metformin treatment is able to reduce the prevalence of metabolic syndrome and its hepatic involvement in young hyperinsulinaemic overweight patients with polycystic ovarian syndrome 126
Long-term metformin treatment is able to reduce the prevalence of metabolic syndrome and its hepatic involvement in young hyperinsulinaemic overweight patients with polycystic ovarian syndrome 126
Prognostic factors for survival in patients with early-intermediate hepatocellular carcinoma undergoing non-surgical therapy: comparison of Okuda, CLIP, and BCLC staging systems in a single Italian centre. 125
Gallstone disease is associated with more severe liver damage in patients with non-alcoholic Fatty liver disease 124
Mediterranean diet and the prevention of non-alcoholic fatty liver disease: Results from a case-control study 124
Braised liver with herbs: the risks of naturopathic hepatoprotection. 122
Silybin combined with phosphatidylcholine and vitamin E in patients with nonalcoholic fatty liver disease: a randomized controlled trial 120
-Nonalcoholic fatty liver disease: defining a common problem 120
The diagnostic performance of PIVKA-II in metabolic and viral hepatocellular carcinoma: A pilot study 120
Impact of new DAA therapy on real clinical practice: A multicenter region-wide cohort study 118
Nonalcoholic fatty liver disease (NAFLD) severity is associated to a nonhemostatic contribution and proinflammatory phenotype of platelets 118
A machine-learning parsimonious multivariable predictive model of mortality risk in patients with Covid-19 117
Different biochemical patterns in type II and type III mixed cryoglobulinemia in HCV positive patients 117
Sentinel biomarkers in HCV positive patients with mixed cryoglobulinemia 117
Project for interventional Oncology LArge-database in liveR Hepatocellular carcinoma - Preliminary CT-based radiomic analysis (POLAR Liver 1.1) 117
Epidemiological trends and trajectories of MAFLD-associated hepatocellular carcinoma 2002-2033: the ITA.LI.CA database 116
Alcoholic and nonalcoholic forms of fatty liver disease. 115
Gastrointestinal symptoms and digestive comorbidities in an Italian cohort of patients with COVID-19 115
A novel ABCB11 variant in compound heterozygosity: BRIC2 or PFIC2? 114
Safety and efficacy of ombitasvir/paritaprevir/ritonavir/dasabuvir plus ribavirin in patients over 65 years with HCV genotype 1 cirrhosis 114
Hug sign in intraprocedural cone-beam-CT to predict short-term response to combined treatment of hepatocellular carcinoma 112
Liver transplantation in alcoholic patients: Impact of an alcohol addiction unit within a liver transplant center 111
Hepatic mitochondrial beta-oxidation in patients with nonalcoholic steatohepatitis assessed by 13C-octanoate breath test. 110
A case of variant angina in a patient under chronic treatment with sorafenib 110
A giant calcified hepatic mass 110
Impact of Gut Microbiota on Obesity, Diabetes, and Cardiovascular Disease Risk 109
Socio-demographic determinants of coinfections by HIV, hepatitis B and hepatitis C viruses in central Italian prisoners. 108
Gender affects 13C-ketoisocaproic acid breath test 108
Machine Learning-Assisted FTIR Analysis of Circulating Extracellular Vesicles for Cancer Liquid Biopsy 107
Is coeliac disease a confounding factor in the diagnosis of NASH? 107
A "systems medicine" approach to the study of non-alcoholic fatty liver disease 107
COVID-19 and hepatic involvement: The liver as a main actor of the pandemic novel 107
Waiting list mortality and 5-year transplant survival benefit of patients with MASLD: An Italian liver transplant registry study 106
FREE LIGHT CHAINS: A NEW POTENTIAL BIOMARKER FOR DISEASE STRATIFICATION IN NON-ALCOHOLIC STEATOHEPATITIS 105
Drug-induced hepatitis 105
A Phase 3, Randomized, Controlled Trial of Resmetirom in NASH with Liver Fibrosis 104
A case-control study on the effect of metabolic gene polymorphisms, nutrition, and their interaction on the risk of non-alcoholic fatty liver disease 104
Drug-induced liver injury 2017: the diagnosis is not easy but always to keep in mind 104
The role of antiplatelet therapies on incidence and mortality of hepatocellular carcinoma 103
Diabetes and Insulin Therapy, but Not Metformin, Are Related to Hepatocellular Cancer Risk 103
Telomerase reverse transcriptase germline mutations and hepatocellular carcinoma in patients with nonalcoholic fatty liver disease 103
The role of elastography in non-Alcoholic fatty liver disease 103
Gut-liver axis and microbiota in NAFLD: insight pathophysiology for novel therapeutic target 102
Totale 15.729
Categoria #
all - tutte 150.614
article - articoli 0
book - libri 0
conference - conferenze 0
curatela - curatele 0
other - altro 0
patent - brevetti 0
selected - selezionate 0
volume - volumi 0
Totale 150.614


Totale Lug Ago Sett Ott Nov Dic Gen Feb Mar Apr Mag Giu
2020/2021662 0 0 0 0 0 52 127 21 151 67 218 26
2021/20221.565 46 112 49 178 111 35 24 235 57 98 295 325
2022/20234.189 436 420 240 452 424 566 283 334 448 271 237 78
2023/20243.093 238 800 109 176 159 337 222 106 45 216 266 419
2024/20257.573 151 124 527 243 551 304 319 620 1.308 718 1.507 1.201
2025/20269.326 2.480 608 1.152 1.780 2.533 773 0 0 0 0 0 0
Totale 31.569